Skandinaviska Enskilda Banken (SEB)’s Sana Biotechnology SANA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-289,273	Closed	-$787K	–	872
2025 Q2	$787K	Hold	289,273	–	–	﹤0.01%	668
2025 Q1	$483K	Buy	289,273 +99,801	+53%	+$279K	﹤0.01%	694
2024 Q4	$305K	Sell	189,472 -394,017	-68%	-$1.17M	﹤0.01%	734
2024 Q3	$2.43M	Hold	583,489	–	–	0.01%	551
2024 Q2	$3.19M	Hold	583,489	–	–	0.02%	469
2024 Q1	$5.83M	Buy	583,489 +355,489	+156%	+$2.66M	0.03%	372
2023 Q4	$930K	Sell	228,000 -85,900	-27%	-$316K	0.01%	704
2023 Q3	$1.22M	Buy	+313,900	New	+$1.69M	0.01%	648

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s SANA Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Sana Biotechnology (SANA) in Q3 2025, closing a stake of 289,273 shares — an estimated $787K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in SANA in Q3 2023 and held it in 8 quarters. The position peaked at $5.83M in Q1 2024. 178 funds tracked by Wall St. Rank hold SANA as of Q3 2025.

Skandinaviska Enskilda Banken (SEB) reported no remaining Sana Biotechnology position as of Q3 2025 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 289,273 Sana Biotechnology shares in Q3 2025, an estimated $787K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Sana Biotechnology in Q3 2023 and held it in 8 quarters.
Skandinaviska Enskilda Banken (SEB)'s Sana Biotechnology position peaked at $5.83M in Q1 2024.
178 funds tracked by Wall St. Rank held Sana Biotechnology as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.